Keywords: Bristol-Myers Squibb, Baraclude, Hepatitis B, USA, FDA

US FDA approves expanded use of Bristol-Myers Baraclude for chronic hepatitis B

Article | 20 October 2010

Print This

The US Food and Drug Administration has approved drug major Bristol-Myers Squibb’s (NYSE: BMY) supplemental New Drug Application ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in